Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Common Equity (2016 - 2025)

PAVmed has reported Common Equity over the past 6 years, most recently at $22.3 million for Q4 2025.

  • For Q4 2025, Common Equity rose 417.08% year-over-year to $22.3 million; the TTM value through Dec 2025 reached $22.3 million, up 417.08%, while the annual FY2025 figure was $22.3 million, 417.08% up from the prior year.
  • Common Equity for Q4 2025 was $22.3 million at PAVmed, down from $22.5 million in the prior quarter.
  • Over five years, Common Equity peaked at $79.4 million in Q4 2021 and troughed at -$24.0 million in Q4 2023.
  • A 5-year average of $19.8 million and a median of $22.4 million in 2025 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: soared 16890.27% in 2021 and later plummeted 2146.02% in 2024.
  • Year by year, Common Equity stood at $79.4 million in 2021, then plummeted by 86.23% to $10.9 million in 2022, then tumbled by 319.66% to -$24.0 million in 2023, then skyrocketed by 70.72% to -$7.0 million in 2024, then soared by 417.08% to $22.3 million in 2025.
  • Business Quant data shows Common Equity for PAVM at $22.3 million in Q4 2025, $22.5 million in Q3 2025, and $28.2 million in Q2 2025.